Expression of vascular endothelial growth factor (VEGF) in locally invasive prostate cancer is prognostic for radiotherapy outcome.
dc.contributor.author | Green, Melanie M | |
dc.contributor.author | Hiley, Crispin T | |
dc.contributor.author | Shanks, Jonathan H | |
dc.contributor.author | Bottomley, Ian C | |
dc.contributor.author | West, Catharine M L | |
dc.contributor.author | Cowan, Richard A | |
dc.contributor.author | Stratford, Ian J | |
dc.date.accessioned | 2009-06-19T13:39:03Z | |
dc.date.available | 2009-06-19T13:39:03Z | |
dc.date.issued | 2007-01-01 | |
dc.identifier.citation | Expression of vascular endothelial growth factor (VEGF) in locally invasive prostate cancer is prognostic for radiotherapy outcome. 2007, 67 (1):84-90 Int. J. Radiat. Oncol. Biol. Phys. | en |
dc.identifier.issn | 0360-3016 | |
dc.identifier.pmid | 17189065 | |
dc.identifier.doi | 10.1016/j.ijrobp.2006.08.077 | |
dc.identifier.uri | http://hdl.handle.net/10541/71038 | |
dc.description.abstract | PURPOSE: Vascular endothelial growth factor (VEGF) is an important hypoxia-inducible pro-angiogenic protein that has been linked with an adverse survival outcome after radiotherapy in other cancer types: we hypothesized that this may also occur in prostate cancer. A retrospective study was, therefore, carried out to evaluate the potential of tumor VEGF expression to predict radiotherapy outcome in patients with high-risk prostate cancer. METHODS AND MATERIALS: Fifty patients with locally advanced (T3 N0 M0) tumors of Gleason score > or =6, and who received radiotherapy alone as primary treatment for their disease, were studied. Vascular endothelial growth factor expression was assessed on pretreatment diagnostic tumor biopsies using a semiquantitative immunohistochemical scoring system. The results were analyzed in relation to clinicopathologic factors and patient outcome including biochemical failure and disease-specific mortality. RESULTS: High VEGF expression was associated with a poor prognosis: in univariate log rank analysis, VEGF was the only significant prognostic factor for disease-specific survival (p = 0.035). High VEGF expression also associated with increased Gleason score (p = 0.02), but not posttreatment biochemical failure. CONCLUSION: High tumor expression of VEGF identified patients at high risk of failure of treatment with radiotherapy. These patients might benefit from additional treatment approaches incorporating anti-angiogenic or hypoxia-specific agents. | |
dc.language.iso | en | en |
dc.subject | Cancer Proteins | en |
dc.subject | Prostatic Cancer | en |
dc.subject.mesh | Aged | |
dc.subject.mesh | Disease-Free Survival | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Linear Models | |
dc.subject.mesh | Male | |
dc.subject.mesh | Neoplasm Proteins | |
dc.subject.mesh | Prognosis | |
dc.subject.mesh | Prostate | |
dc.subject.mesh | Prostatic Neoplasms | |
dc.subject.mesh | Retrospective Studies | |
dc.subject.mesh | Treatment Outcome | |
dc.subject.mesh | Vascular Endothelial Growth Factor A | |
dc.title | Expression of vascular endothelial growth factor (VEGF) in locally invasive prostate cancer is prognostic for radiotherapy outcome. | en |
dc.type | Article | en |
dc.contributor.department | Department of Pharmacy and Pharmaceutical Sciences, Coupland III, University of Manchester, Oxford Road, Manchester, UK. | en |
dc.identifier.journal | International Journal of Radiation Oncology, Biology, Physics | en |
html.description.abstract | PURPOSE: Vascular endothelial growth factor (VEGF) is an important hypoxia-inducible pro-angiogenic protein that has been linked with an adverse survival outcome after radiotherapy in other cancer types: we hypothesized that this may also occur in prostate cancer. A retrospective study was, therefore, carried out to evaluate the potential of tumor VEGF expression to predict radiotherapy outcome in patients with high-risk prostate cancer. METHODS AND MATERIALS: Fifty patients with locally advanced (T3 N0 M0) tumors of Gleason score > or =6, and who received radiotherapy alone as primary treatment for their disease, were studied. Vascular endothelial growth factor expression was assessed on pretreatment diagnostic tumor biopsies using a semiquantitative immunohistochemical scoring system. The results were analyzed in relation to clinicopathologic factors and patient outcome including biochemical failure and disease-specific mortality. RESULTS: High VEGF expression was associated with a poor prognosis: in univariate log rank analysis, VEGF was the only significant prognostic factor for disease-specific survival (p = 0.035). High VEGF expression also associated with increased Gleason score (p = 0.02), but not posttreatment biochemical failure. CONCLUSION: High tumor expression of VEGF identified patients at high risk of failure of treatment with radiotherapy. These patients might benefit from additional treatment approaches incorporating anti-angiogenic or hypoxia-specific agents. |